Table 2.
Baseline characteristics of the TnT positive patient population arranged according to the quartiles of 25(OH)D.
| Characteristics n (%) | Quartiles of 25(OH)D | P value | |||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | ||
| 25(OH)D (nmol/L)* | 30.2 ± 6.2 | 44.9 ± 3.5 | 56.6 ± 3.6 | 78.1 ± 13.2 | <0.001 |
| 25(OH)D (ng/mL)* | 12.1 ± 2.5 | 18.0 ± 1.4 | 22.6 ± 1.4 | 31.2 ± 5.3 | <0.001 |
| Omega-3 Index* | 6.1 ± 1.6 | 6.4 ± 1.6 | 6.9 ± 1.9 | 7.5 ± 2.2 | <0.001 |
| Age, years* | 72.5 ± 14.8 | 72.6 ± 13.5 | 71.5 ± 13.8 | 71.2 ± 11.0 | 0.809 |
| Male, n (%) | 64 (55.2) | 81 (69.2) | 73 (62.4) | 86 (74.1) | 0.015 |
| Smoking status, n (%) | 0.047 | ||||
| Current smoker, n (%) | 36 (31.0) | 37 (31.6) | 35 (29.9) | 30 (25.9) | |
| Past smoker, n (%) | 30 (25.9) | 42 (35.9) | 35 (29.9) | 53 (45.7) | |
| Never smoked, n (%) | 50 (43.1) | 38 (32.5) | 47 (40.2) | 33 (28.4) | |
| Angina pectoris, n (%) | 49 (42.2) | 48 (41.0) | 52 (44.4) | 51 (44.0) | 0.949 |
| CHF, n (%) | |||||
| Killip Class 2–4 | 56 (48.3) | 27 (23.1) | 30 (25.6) | 32 (27.6) | <0.001 |
| History of previous MI, n (%) | 46 (39.7) | 37 (31.6) | 35 (29.9) | 38 (32.8) | 0.413 |
| CABG, n (%) | 11 (9.5) | 7 (6.0) | 12 (10.3) | 12 (10.3) | 0.612 |
| PCI, n (%) | 9 (7.8) | 9 (7.7) | 7 (6.0) | 10 (8.6) | 0.893 |
| Hypertension, n (%) | 48 (41.4) | 47 (40.2) | 52 (44.4) | 49 (42.2) | 0.926 |
| History of DM 1, n (%) | 0 (0.0) | 2 (1.7) | 0 (0.0) | 4 (3.4) | 0.058 |
| History of DM 2, n (%) | 26 (22.4) | 19 (16.2) | 19 (16.2) | 9 (7.8) | 0.023 |
| STEMI, n (%) | 29 (25.0) | 35 (29.9) | 30 (25.6) | 33 (28.4) | 0.813 |
| eGFR (μmol L−1)* | 59.7 ± 23.2 | 59.8 ± 22.3 | 62.5 ± 23.3 | 63.9 ± 23.5 | 0.418 |
| Cholesterol/statin, n (%) | 53 (45.7) | 54 (46.2) | 52 (44.4) | 50 (43.1) | 0.967 |
| Beta-blocker, n (%) | 40 (34.5) | 39 (33.3) | 35 (29.9) | 34 (29.3) | 0.793 |
| Known CHD, n (%) | 80 (69.0) | 71 (60.7) | 76 (65.0) | 72 (62.1) | 0.566 |
| BMI (kg/m2)* | 25.7 ± 4.5 | 25.9 ± 4.6 | 25.6 ± 4.3 | 25.3 ± 3.9 | 0.714 |
| BNP quartiles | 0.778 | ||||
| Q1 | 15 (13.8) | 17 (15.0) | 22 (19.5) | 23 (21.3) | |
| Q2 | 24 (22.0) | 23 (20.4) | 25 (22.1) | 24 (22.2) | |
| Q3 | 26 (23.9) | 34 (30.1) | 32 (28.3) | 26 (24.1) | |
| Q4 | 44 (40.4) | 39 (34.5) | 34 (30.1) | 35 (32.4) | |
| hsCRP quartiles | 0.698 | ||||
| Q1 | 18 (15.5) | 22 (18.8) | 19 (16.2) | 27 (23.3) | |
| Q2 | 24 (20.7) | 27 (23.1) | 31 (26.5) | 27 (23.3) | |
| Q3 | 32 (27.6) | 36 (30.8) | 36 (30.8) | 32 (27.6) | |
| Q4 | 42 (36.2) | 32 (27.4) | 31 (26.5) | 30 (25.9) | |
*Mean ± SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation myocardial infarction; TnT, troponin T; eGFR, estimated glomerular filtration rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic peptide; hsCRP, high sensitivity C-reactive protein.